Novavax director Rachel King sells $37,435 in stock
Novavax director Rachel King sells $37,435 in stock
Novavax director Rachel King sells $37,435 in stock
Rachel K. King, a director at Novavax Inc. (NASDAQ:NVAX), recently sold 4,150 shares of the company's common stock. The shares were sold at an average price of $9.0205 each, totaling approximately $37,435. Following this transaction, King now holds 14,770 shares directly. The sale was executed on December 13, 2024, according to the latest SEC filing.The transaction comes amid significant stock volatility, with NVAX shares down 38% over the past six months. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available through their comprehensive Pro Research Report. According to InvestingPro, which offers 8+ additional expert tips for NVAX, the company's market capitalization stands at $1.36 billion.
Analysts from B.Riley and H.C. Wainwright have maintained their Buy ratings on Novavax, with B.Riley reducing its price target. The company's third-quarter earnings report revealed a decrease in revenues to $85M, down from $187M in the same quarter of the previous year. These are recent developments in Novavax's ongoing efforts to remain competitive in the vaccine market.
Rachel K. King, a director at Novavax Inc. (NASDAQ:NVAX), recently sold 4,150 shares of the company's common stock. The shares were sold at an average price of $9.0205 each, totaling approximately $37,435. Following this transaction, King now holds 14,770 shares directly. The sale was executed on December 13, 2024, according to the latest SEC filing.The transaction comes amid significant stock volatility, with NVAX shares down 38% over the past six months. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available through their comprehensive Pro Research Report. According to InvestingPro, which offers 8+ additional expert tips for NVAX, the company's market capitalization stands at $1.36 billion.
Analysts from B.Riley and H.C. Wainwright have maintained their Buy ratings on Novavax, with B.Riley reducing its price target. The company's third-quarter earnings report revealed a decrease in revenues to $85M, down from $187M in the same quarter of the previous year. These are recent developments in Novavax's ongoing efforts to remain competitive in the vaccine market.